MHRA
2 stories
-
healthUK Approves First Daily Oral GLP-1 Semaglutide for Obesity Treatment
Novo Nordisk secures UK approval for daily oral semaglutide, offering a non-injectable alternative for obesity management with significant weight loss results in clinical trials.
-
healthUnregulated Peptide 'Grey Market' Fuels Self-Injection Trend
Millions are injecting peptides sold 'for research purposes only,' bypassing safety regulations and risking serious health consequences.